A61K 9/124
Characterised by the propellant
Official title: {characterised by the propellant}
A61K9/124 (Characterised by the propellant) appears on 285 US grants and 405 published applications in this corpus.
Search patents in A61K- Granted patents
- 285
- Published applications
- 405
- Assignees
- 142
- Inventors
- 413
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 4 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 11 | 0 |
| 1998 | 6 | 0 |
| 1999 | 5 | 0 |
| 2000 | 6 | 0 |
| 2001 | 9 | 0 |
| 2002 | 10 | 10 |
| 2003 | 6 | 8 |
| 2004 | 5 | 10 |
| 2005 | 1 | 13 |
| 2006 | 3 | 8 |
| 2007 | 3 | 13 |
| 2008 | 0 | 9 |
| 2009 | 5 | 12 |
| 2010 | 4 | 15 |
| 2011 | 4 | 12 |
| 2012 | 8 | 14 |
| 2013 | 8 | 22 |
| 2014 | 18 | 22 |
| 2015 | 12 | 26 |
| 2016 | 17 | 26 |
| 2017 | 16 | 24 |
| 2018 | 12 | 16 |
| 2019 | 18 | 33 |
| 2020 | 21 | 24 |
| 2021 | 17 | 19 |
| 2022 | 7 | 19 |
| 2023 | 12 | 13 |
| 2024 | 10 | 14 |
| 2025 | 8 | 17 |
| 2026 | 9 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- VIP and VIP agonists, nanoparticles, and uses in inflammatory T-cell mediated disease21 Jul 2026US 12,685,761 B2Emory University
- Compositions, gels and foams with rheology modulators and uses thereof23 Jun 2026US 12,661,407 B2Journey Medical Corporation
- Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent2 Jun 2026US 12,642,779 B1Amphastar Pharmaceuticals, Inc.
- Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases2 Jun 2026US 12,642,802 B2Incyte Corporation
- Carbonated aerosol external preparation for skin31 Mar 2026US 12,589,110 B2Kao Corporation
- Metered dose inhalers and high-dose suspensions27 Aug 2026US 2026/0249027 A1Kindeva Drug Delivery L. P.
- Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases16 Jul 2026US 2026/0199359 A1Incyte Corporation
- Pharmaceutical composition25 Jun 2026US 2026/0174734 A1Mexichem Fluor S.A. De C.V.
- Delivery of liquid composition and oxygen4 Jun 2026US 2026/0151336 A1BOA Refinance Corp, LLC
- Metered dose inhalers and suspension compositions16 Apr 2026US 2026/0102344 A1Kindeva Drug Delivery L. P.
Most cited
By later US patents
- Medicinal aerosol formulations220US 5,225,183 ARiker Laboratories, Inc. · 1993
- Methods and apparatus for fine particle formation201US 6,095,134 ABoard of Regents, The University of · 2000
- Methods for fine particle formation187US 5,639,441 ABoard of Regents of the University of Colorado · 1997
- Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations184US 5,118,494 AMinnesota Mining and Manufacturing Company · 1992
- Penetrating pharmaceutical foam145US 7,700,076 B2Foamix Ltd. · 2010